1. In Vivo

J&J Renews Commitment To Devices With Synthes Deal

Rumors that Johnson & Johnson was looking to exit cardiovascular devices and perhaps go so far as to divest their entire device business apparently can be put to rest in light of the company’s recently announced plans to acquire orthopedics leader Synthes Inc.

Rumors that Johnson & Johnson was looking to exit cardiovascular devices and perhaps go so far as to divest its entire device business apparently can be put to rest in light of the company's recently announced plans to acquire orthopedics leader Synthes Inc.[See Deal] The $21.7 billion deal – the largest acquisition in J&J's history – bolsters the company's lagging DePuy Synthes orthopedics division by enhancing its spine business and making it the leader in the trauma market, a relatively small but fast-growing orthopedic sector.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Reforming The Rx Rulers: A New Script For PBMs

 
• By Andrew Cox

As PBMs shift to value-based contracts, federal and state efforts seek to reduce drug costs, increase transparency and tackle anticompetitive practices.

Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis Asset

 
• By David Wild

Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.